Vivus' Qnexa Gets "Complete Response" Letter From FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA wants more data on risk of birth defects, cardiovascular effects, but doesn't ask for new clinical trials - at least for now.